News | Breast Imaging | July 06, 2020

First AccuBoost Digital Installation for Radiation Treatment of Breast Cancer

Advanced Radiation Therapy has completed the first AccuBoost Digital installation at Rhode Island Hospital (RIH). This state-of-the-art platform leverages the superior resolution of digital mammography in the delivery of breast radiation therapy.

July 6, 2020 — Advanced Radiation Therapy has completed the first AccuBoost Digital installation at Rhode Island Hospital (RIH). This state-of-the-art platform leverages the superior resolution of digital mammography in the delivery of breast radiation therapy. The instantaneous image acquisition of the digital design reduces the treatment time and improves patient workflow.

The AccuBoost treatment was developed for women choosing to retain their breast through a treatment course known as Breast Conserving Therapy (BCT). The clinical team at RIH has over a decade of experience in offering the AccuBoost treatment on the first generation platform with excellent clinical results. RIH has acquired the new Digital solution to improve the treatment workflow, patient experience, and benefit from the updated user interface. This upgraded platform is the ultimate option for women with early-stage breast cancer.

 “AccuBoost Digital takes adaptive brachytherapy to the next level and truly delivers a personalized daily treatment for every patient,” stated Adam Brandow, vice resident of technology of Advanced Radiation Therapy. He added, “Whether for the Boost portion of XBRT or for APBI, the streamlined workflow improves both the physician and patient experience. This unique technology enables an adaptive treatment with advanced targeting capability for the radiation oncologist to identify the target tissue at risk and deliver a conformal radiation treatment while minimizing stray radiation to neighboring organs such as the heart and lungs.”

For more information: www.accuboost.com

 

Related Content

JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

Table 1. JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

News | Coronavirus (COVID-19) | July 31, 2020
July 31, 2020 — An article published in JAMA...
It covers every major modality, including breast imaging/mammography, fixed and portable C-arms (cath, IR/angio, hybrid, OR), CT, MRI, nuclear medicine, radiographic fluoroscopy, ultrasound and X-ray
News | Radiology Imaging | July 29, 2020
July 29, 2020 — IMV Medical Information, part of Scien...
It has been estimated that the overwhelming focus on COVID-19 could cause up to 35,000 excess cancer deaths in the UK during the next 12 months, and  Zegami, the Oxford University data visualization spin-out which has worked on several projects focused on the detection, diagnosis, or management of cancer, is calling for greater use of technology to speed up the process of diagnosis and treatment.

Getty Images

News | Radiation Oncology | July 29, 2020
July 29, 2020 — It has been estimated that the overwhelming focus on...
Zebra Medical Vision announced its sixth FDA 510(k) clearance for its mammography solution, HealthMammo, which has already received a CE mark. Zebra Medical’s algorithm empowers breast radiologists by prioritizing and identifying suspicious mammograms, providing a safety net for radiologists. The suspicious mammograms are identified faster and read earlier than the current “first-in first-out” standard of care. 
News | Breast Imaging | July 27, 2020
July 26, 2020 —  Zebra Medical Vision announced its sixth FDA 510
In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.  http://jnm.snmjournals.org/content/early/2020/07/16/jnumed.120.249748.full.pdf+html

In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.

 

News | Coronavirus (COVID-19) | July 22, 2020 | Dave Fornell, Editor
July 22, 2020 — One of the first studies has been published that looks at the use of...
World's largest radiation oncology meeting will offer full conference on interactive platform October 25-28, 2020
News | ASTRO | July 09, 2020
July 9, 2020 — Registration opens today for the American Society for Radiation Oncology's (...
Simulation finds starting at age 30 with MRI and mammography to be the preferred strategy; starting at 25 prevented marginally more deaths, but with more testing and emotional stress

Getty Images

News | Breast Imaging | July 09, 2020
July 9, 2020 — Chest radiation is used to treat children with Hodgkin and non-Hodgkin lymphoma as well as lung metast